Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma

Lymphoma Clinical Trial

Official title:

An Intention-to-Treat Study of Salvage Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of High-Risk or Relapsed Hodgkin Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00574496
• Other study ID #: 07-147
• Secondary ID: MSKCC-07147
• Status: Completed
• Phase: Phase 2
• Start date: November 13, 2007
• Est. completion date: August 2, 2022

Study information

• Verified date: October 2022
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine, mycophenolate mofetil, and methotrexate before and after transplant may stop this from happening.

PURPOSE: This phase II trial is studying how well combination chemotherapy followed by donor stem cell transplant works in treating patients with relapsed or high-risk primary refractory Hodgkin lymphoma.

Description:

OUTLINE: Patients are stratified according to response to prior therapy and risk factors (those with presence of all 3 risk factors and failed primary therapy or primary progressive disease vs. patients who relapse more than 100 days after an autologous stem cell transplant).

• Salvage chemotherapy (IGV or MOPP): Patients who have previously received mechlorethamine hydrochloride receive IGV; patients who have previously received a gemcitabine-based regimen receive MOPP.

• IGV (ifosfamide, gemcitabine hydrochloride, and vinorelbine ditartrate): Patients receive IGV combination chemotherapy comprising ifosfamide IV on days 1-4, gemcitabine hydrochloride IV on days 1 and 4, and vinorelbine ditartrate IV on day

1. Treatment repeats every 2-3 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity.

• MOPP (mechlorethamine hydrochloride, vincristine, procarbazine hydrochloride, and prednisone): Patients receive MOPP combination chemotherapy comprising mechlorethamine hydrochloride IV on days 1 and 8, vincristine IV on days 1 and 8, oral procarbazine hydrochloride on days 1-14, and oral prednisone on days 1-14. Treatment repeats every 4 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.

Patients with no progression of disease after salvage chemotherapy (at allograft work-up) proceed to allogeneic hematopoietic stem cell transplantation [AHSCT]* within 60 days after completion of salvage chemotherapy.

NOTE: *Patients with a nodal mass > 5 cm that has not ben previously irradiated and in the absence of extranodal disease may undergo involved-field radiotherapy twice daily for 2 weeks, prior to AHSCT.

• AHSCT with reduced-intensity or non-myeloablative conditioning: Patients achieving partial response or stable disease after salvage therapy receive fludarabine phosphate IV over 30 minutes on days -6 to -2; melphalan IV over 15 minutes on days -6 and -5; and undergo AHSCT on day 0 (reduced-intensity conditioning). Patients achieving complete response after salvage therapy receive fludarabine phosphate IV over 30 minutes on days -6 to -2; cyclophosphamide IV over 15 minutes on day -6; total-body irradiation over 20-30 minutes on day -1; and undergo AHSCT on day 0 (non-myeloablative conditioning).

• Graft-vs-host disease prophylaxis: Patients with related or unrelated donors receive cyclosporine IV over 2-4 hours or orally on days -3 to 100 followed by a taper, mycophenolate mofetil IV or orally on days -3 to 46 followed by a taper, and methotrexate IV on days 1, 3, 6, and 11.

Patients who received umbilical cord blood receive cyclosporine and mycophenolate mofetil as above (no methotrexate).

Follow-up period of 2 years post-transplant.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: August 2, 2022
• Est. primary completion date: August 2, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 13 Years to 65 Years

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed classical Hodgkin lymphoma, including CD20+ disease

• No lymphocyte predominant histology

• Primary refractory or relapsed disease with all 3 risk factors, failed platinum-based chemotherapy, or disease relapsed more than 100 days after autologous stem cell transplantation, proven by biopsy or fine-needle aspiration (cytology) of an involved site

• Risk factors are defined as B-symptoms, extranodal sites of disease, and disease remission lasting < 1 year after first-line therapy

• Failed doxorubicin hydrochloride or mechlorethamine hydrochloride-containing front-line therapy

• Fludeoxyglucose F 18-PET scan demonstrating PET-avid disease

• No more than 2 prior salvage chemotherapy regimens (for patients proceed to allogeneic hematopoietic stem cell transplantation [AHSCT])

• Donor available meeting 1 of the following criteria (for patients proceed to AHSCT):

• HLA-matched or one allele mismatched related donor

• Genotypically or phenotypically matched at = 9/10 of the A, B, C, DRB1, and DQB1 loci, as tested by high resolution

• Peripheral blood stem cells (PBSC) collected

• HLA-matched unrelated donor

• Matched at = 9/10 (allele mismatch only) of the A, B, C, DRB1, and DQB1 loci, as tested by high resolution

• PBSC or bone marrow collected

• Umbilical cord blood (2 units)

• must be = 4/6 HLA-A, B antigen, and DRB1 allele matched with recipient

PATIENT CHARACTERISTICS:

• Platelet count > 50,000/mm^3

• ANC > 1,000/mm^3

• Cardiac ejection fraction > 50% (for patients = 18 years of age)

• Fractional shortening > 50% by echocardiogram* (for patients < 18 years of age)

• Adjusted diffusing capacity > 50% on pulmonary function testing*

• Serum creatinine < 1.5 mg/dL

• Creatinine clearance = 50 mL/min

• Total bilirubin < 2.0 mg/dL in the absence of a history of Gilbert disease

• HIV I and II negative

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• Karnofsky performance status (PS) = 70% or Lansky PS = 70% (for patients proceed to AHSCT)

• No active and uncontrolled infection at time of transplantation including active infection with Aspergillus or other mold (for patients proceed to AHSCT) NOTE: *measured since last chemotherapy

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No prior allogeneic transplantation

• No more than 1 prior autologous transplantation

• No inability to complete planned cytoreduction due to therapy complications

Related Conditions & MeSH terms

• Hodgkin Disease
• Lymphoma

Intervention

Drug:
• cyclophosphamide

• cyclosporine

• fludarabine phosphate

• gemcitabine hydrochloride

• ifosfamide

• mechlorethamine hydrochloride

• melphalan

• methotrexate

• mycophenolate mofetil

• prednisone

• procarbazine hydrochloride

• vincristine sulfate

• vinorelbine tartrate

Procedure:
• allogeneic bone marrow transplantation

• allogeneic hematopoietic stem cell transplantation

• nonmyeloablative allogeneic hematopoietic stem cell transplantation

• peripheral blood stem cell transplantation

• umbilical cord blood transplantation

Radiation:
• total-body irradiation

Locations

Country	Name	City	State
United States	Memorial Sloan-Kettering Cancer Center	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free Survival at 1 Year	Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions	1 year
Secondary	Overall Survival		up to 8 years
Secondary	Disease Relapse or Progression as Measured by CT Scan or PET		3 years

External Links

•   Memorial Sloan Kettering Cancer Center